382 related articles for article (PubMed ID: 22395672)
1. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.
Mosam A; Shaik F; Uldrick TS; Esterhuizen T; Friedland GH; Scadden DT; Aboobaker J; Coovadia HM
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):150-7. PubMed ID: 22395672
[TBL] [Abstract][Full Text] [Related]
2. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.
Gbabe OF; Okwundu CI; Dedicoat M; Freeman EE
Cochrane Database Syst Rev; 2014 Aug; 8(8):CD003256. PubMed ID: 25221796
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.
Gbabe OF; Okwundu CI; Dedicoat M; Freeman EE
Cochrane Database Syst Rev; 2014; (9):CD003256. PubMed ID: 25313415
[TBL] [Abstract][Full Text] [Related]
4. Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi.
Herce ME; Kalanga N; Wroe EB; Keck JW; Chingoli F; Tengatenga L; Gopal S; Phiri A; Mailosi B; Bazile J; Beste JA; Elmore SN; Crocker JT; Rigodon J
J Int AIDS Soc; 2015; 18(1):19929. PubMed ID: 26028156
[TBL] [Abstract][Full Text] [Related]
5. As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.
Hosseinipour MC; Kang M; Krown SE; Bukuru A; Umbleja T; Martin JN; Orem J; Godfrey C; Hoagland B; Mwelase N; Langat D; Nyirenda M; MacRae J; Borok M; Samaneka W; Moses A; Mngqbisa R; Busakhala N; Martínez-Maza O; Ambinder R; Dittmer DP; Nokta M; Campbell TB;
Clin Infect Dis; 2018 Jul; 67(2):251-260. PubMed ID: 29365083
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.
Krown SE; Moser CB; MacPhail P; Matining RM; Godfrey C; Caruso SR; Hosseinipour MC; Samaneka W; Nyirenda M; Busakhala NW; Okuku FM; Kosgei J; Hoagland B; Mwelase N; Oliver VO; Burger H; Mngqibisa R; Nokta M; Campbell TB; Borok MZ;
Lancet; 2020 Apr; 395(10231):1195-1207. PubMed ID: 32145827
[TBL] [Abstract][Full Text] [Related]
7. Health-Related Quality of Life in Patients Treated With Antiretroviral Therapy Only Versus Chemotherapy and Antiretroviral Therapy for HIV-Associated Kaposi Sarcoma: A Randomized Control Trial.
Shaik F; Uldrick TS; Esterhuizen T; Mosam A
J Glob Oncol; 2018 Oct; 4():1-9. PubMed ID: 30354935
[TBL] [Abstract][Full Text] [Related]
8. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
9. AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe.
Nelson BC; Borok MZ; Mhlanga TO; Makadzange AT; Campbell TB
Int J Infect Dis; 2013 Oct; 17(10):e902-6. PubMed ID: 23809198
[TBL] [Abstract][Full Text] [Related]
10. Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy.
Nyirenda M; Ngongondo M; Kang M; Umbleja T; Krown SE; Godfrey C; Samaneka W; Mngqibisa R; Hoagland B; Mwelase N; Caruso S; Martinez-Maza O; Dittmer DP; Borok M; Hosseinipour MC; Campbell TB;
J Acquir Immune Defic Syndr; 2020 Aug; 84(4):422-429. PubMed ID: 32265361
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.
Gill J; Bourboulia D; Wilkinson J; Hayes P; Cope A; Marcelin AG; Calvez V; Gotch F; Boshoff C; Gazzard B
J Acquir Immune Defic Syndr; 2002 Dec; 31(4):384-90. PubMed ID: 12447008
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for treating life-threatening Kaposi sarcoma during pregnancy in HIV-positive women in low income countries.
Bacha JM; El-Mallawany NK; Slone JS; Wilkinson JP; Mehta PS; Campbell LR
Int J STD AIDS; 2020 Jul; 31(8):724-734. PubMed ID: 32493141
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.
Borok M; Fiorillo S; Gudza I; Putnam B; Ndemera B; White IE; Gwanzura L; Schooley RT; Campbell TB
Clin Infect Dis; 2010 Aug; 51(3):342-9. PubMed ID: 20572760
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for AIDS-related and endemic African Kaposi's sarcoma in southern Africa.
Stein ME; Lachter J; Spencer D; Bezwoda WR
Int J Dermatol; 1995 Oct; 34(10):729-32. PubMed ID: 8537166
[TBL] [Abstract][Full Text] [Related]
16. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy.
Leitch H; Trudeau M; Routy JP
HIV Clin Trials; 2003; 4(2):107-14. PubMed ID: 12671778
[TBL] [Abstract][Full Text] [Related]
17. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
18. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma.
Tam HK; Zhang ZF; Jacobson LP; Margolick JB; Chmiel JS; Rinaldo C; Detels R
Int J Cancer; 2002 Apr; 98(6):916-22. PubMed ID: 11948473
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for Kaposi's sarcoma in human immunodeficiency virus patients after initiation of antiretroviral therapy: A nested case-control study in Kenya.
Lupia R; Wabuyia PB; Otiato P; Fang CT; Tsai FJ
J Microbiol Immunol Infect; 2017 Dec; 50(6):781-788. PubMed ID: 26712092
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.
Cianfrocca M; Lee S; Von Roenn J; Tulpule A; Dezube BJ; Aboulafia DM; Ambinder RF; Lee JY; Krown SE; Sparano JA
Cancer; 2010 Aug; 116(16):3969-77. PubMed ID: 20564162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
